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Intensive Care Management 
in Cerebral Aneurysm and 
Arteriovenous Malformations
Sedef Tavukçu Özkan
Abstract
Aneurysmal subarachnoid hemorrhage is an important group of intracranial 
hemorrhage with a high risk of disability and mortality. The initial amount of 
bleeding, rebleeding, and delayed cerebral ischemia are considered as the most 
important factors in determining the prognosis of aneurysm-induced bleeding. 
In arteriovenous malformations, its location and deep venous drainage play a 
role in the prognosis. Cardiac complications, neurogenic pulmonary edema, 
hypertension, hyperglycemia, infections, and prolonged mechanical ventila-
tion in aneurysmal subarachnoid hemorrhage lead to morbidity and mortality. 
Aneurysm bleeding control, appropriate fluid replacement to ensure euvolemia, 
when necessary external ventricular drainage and/or decompressive craniectomy, 
mannitol or hypertonic saline application, and infection control are the main 
principles of treatment.
Keywords: aneurysmal subarachnoid hemorrhage,  
cerebral arteriovenous malformation, cerebral vasospasm, delayed cerebral ischemia, 
intracranial pressure
1. Definition and etiology
The modern definition of cerebral artery aneurysms began in 1874 with Duret’s 
description of the middle cerebral artery (MCA). It is known that 20% of all 
aneurysms are composed of MCA aneurysms and 90% of aneurysms originate 
from anterior circulation. It is more common in women aged 35–60 years [1]. 
Subarachnoid hemorrhage (SAH) is a major health problem worldwide with a high 
mortality rate. Despite a 17% decrease in case fatality in the last three decades asso-
ciated with improved management strategies, 30-day mortality and sudden death 
rate unfortunately are still high, around 35 and 15%, respectively [2].
Cerebral arteriovenous malformations (AVM) are composed of a complexity of 
abnormal arteries and veins and are a major source of brain hemorrhage, resulting 
in morbidity and mortality, representing a diagnostic and therapeutic challenge in 
young adults. Cerebral AVM generally represents 1 and 3% of the total annual risk 
for epilepsy and bleeding in patients with AVM. The rate risk of bleeding in undam-
aged AVMs is 2.2% per year, and the rate of torn lesions is 4.5% per year. Important 
risk factors for the development of bleeding due to AVM include deep localiza-
tion, deep venous drainage, associated aneurysms, pregnancy, age, and gender. 
Disconnection of arteriovenous malformations from circulation and prevention 
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of epileptic seizures remain the mainstay of treatment. The size, location, and 
presence of deep venous drainage (using the Spetzler-Martin score) determine the 
mortality and management of the arteriovenous malformations.
The most common causes of aneurysm remain hemodynamic instability, 
degenerative changes, vascular injury, atherosclerosis, vasculopathy, high flow, 
arteriovenous malformation, and fistula. In addition, the important risk factors 
for the development of cerebral aneurysms are hypertension, smoking, chronic 
alcohol use, family history of intracranial aneurysms in first-degree relatives, and 
female sex. Autosomal dominant polycystic kidney disease is an inherited sys-
temic disorder that is strongly associated with intracranial aneurysms. Autosomal 
dominant polycystic kidney disease has a prevalence rate 2–4 times higher than 
the general population. Other conditions such as Marfan syndrome, Ehler-Danlos 
syndrome type IV, neurofibromatosis type I, hereditary hemorrhagic telangiectasia, 
Moyamoya disease, pseudoxanthoma elastum, and fibromuscular dysplasia are 
weakly associated with intracranial aneurysms. Multiple aneurysms are detected in 
10–30% of cases. Both localization and type of aneurysm are important consider-
ations in describing the risk for rupture. Aneurysm rupture is directly proportional 
to size, and ruptured aneurysm causes subdural, subarachnoid, or intracranial 
hematoma. 25% of the cases with ruptured aneurysm are lost and 50% of them have 
partial or complete recovery. Overall incidence of mortality and complications in 
ruptured aneurysm is 80%. Risk factors for the formation of and rupture of intra-
cranial aneurysms are shown in Tables 1 and 2 [1, 3, 4].
Aneurysms are classified according to their shape or size.
According to the shape:
1. Saccular (traumatic, mycotic, oncotic, flow-dependent vasculopathy, drug-
induced).
2. Fusiform.
Rupture of intracranial aneurysms Female sex
Smoking
Hypertension
Cocaine abuse
Sympathomimetic drug use
Posterior circulation aneurysms
Type of aneurysms
Giant aneurysms
Table 2. 
Risk factors for the rupture of intracranial aneurysms.
Formation of intracranial aneurysms Hypertension
Smoking
Chronic alcohol use
Family history
Female sex
Polycystic kidney disease
Marfan syndrome
Ehler-Danlos syndrome
Fibromuscular dysplasia
Neurofibromatosis type I
Table 1. 
Risk factors for the formation of intracranial aneurysms.
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3. Dissecting.
According to the size:
1. Small (<15 mm).
2. Large (15–25 mm).
3. Giant (25–50 mm).
4. Super giant (>50 mm).
Saccular berry aneurysms account for 90% of the total aneurysm morphology, 
and their rupture is the most common cause of SAH. Fusiform aneurysms account for 
the remaining 10%, and their most common location is posteriorly. Atherosclerosis 
and dissection are found to be responsible as possible mechanisms for formation of 
fusiform aneurysms.
2. Clinical presentation of subarachnoid hemorrhage
The most common clinical reflection of aneurysm is SAH; it can occur in several 
ways: headache, bilateral temporal hemianopsia and bilateral lower limb weakness, 
unilateral nerve palsy, facial or orbital pain, nosebleed, progressive vision loss 
and/or ophthalmoplegia, and symptoms of brain stem dysfunction. Patients with 
complex middle cerebral artery aneurysms may present with intracranial hemor-
rhage, mass effects, epilepsy, or cerebral ischemia; in addition, the aneurysm may 
be incidentally discovered. A high mortality rate of 65–85% within 2 years has been 
reported, and aneurysm rupture survivors are often left with severe neurological 
deficits [5–9].
In the presence of rupture, aneurysmal SAH may cause coma in 20–30% of 
patients. In “poor-grade” patients, neurologic findings may include extensor pos-
turing and loss of upper brain stem reflexes, and further progression may occur in 
hours from the ictus. A wide light-fixed pupil may indicate oculomotor palsy from 
a ruptured posterior communicating aneurysm or lateral brain stem displacement 
from a hematoma in the temporal or frontal lobe. Pinpoint pupils may indicate the 
presence of an acute hydrocephalus with ventricles often filled with blood. The 
causes of coma after aneurysmal SAH are shown in Table 3.
The severity of SAH is clinically assessed and graded using either the Hunt 
and Hess classification or the World Federation of Neurosurgeons (WFNS) scale 
(Tables 4 and 5). The WFNS, widely used, is a combination of focal neurological  
deficits and the Glasgow coma scale (GCS). Higher grades on both scales are 
• Diffuse ischemic global cortical injury
• Early cerebral edema
• Acute hydrocephalus
• Hematoma in the temporal lobe and brain stem shift
• Hematoma in the pons
• Nonconvulsive status epilepticus
Table 3. 
Causes of coma in aneurysmal subarachnoid hemorrhage.
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associated with the worst outcomes. The WFNS classification provides a more 
objective assessment. The first computerized tomography scan uses the Fisher grad-
ing scale to determine the amount, localization, prognosis, and severity of bleeding 
(Table 6). The risk of vasospasm is high in patients with Grade III and IV SAH.
The overall mortality in patients with SAH is over 30%, and approximately 
10–20% of survivors show functional dependence despite intensive neurological care. 
Several extensive studies have been conducted to improve intensive neurological care 
in patients with SAH [12]. Poor-grade aneurysmal SAH (WFNS Grades IV and V) 
Grade Clinical description
0 Unruptured aneurysm
1 Asymptomatic or minimal headache and slight nuchal rigidity
2 Moderate/severe headache, nuchal rigidity, cranial nerve palsy
3 Drowsiness, confusion, or mild focal deficit
4 Stupor, severe hemiparesis, vegetative disturbance
5 Deep coma, decerebrate rigidity, moribund appearance
Hypertension, diabetes, arteriosclerosis, chronic pulmonary disease, or vasospasm assigns patient to the next less 
favorable category.
Table 4. 
Modified Hunt and Hess classification [13].
Grade Glasgow coma scale score Motor deficit
I 15 Absent
II 14–13 Absent
III 14–13 Present
IV 12–7 Present/Absent
V 6–3 Present/Absent
Source: Ref. [10].
Table 5. 
World Federation of neurosurgeons scale.
Grade Fisher scale % with 
symptomatic 
vasospasm
Modified Fisher 
scale
% with 
symptomatic 
vasospasm
I Focal thin 21% Focal or diffuse 
thin SAH, no IVH
24%
II Diffuse thin SAH 25% Focal or diffuse 
thin SAH, with 
IVH
33%
III Thick SAH present 37% Thick SAH present, 
no IVH
33%
IV Focal or diffuse thin SAH 
with significant ICH or 
IVH
31% Thick SAH present, 
with IVH
40%
Source: Ref. [11].
Table 6. 
Fisher and modified fisher grading scale.
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reflect 20–30% of all aneurysmal SAH. Mortality is commonly associated with neu-
rological injury resulting from the initial bleeding and rebleeding and from delayed 
cerebral ischemia (DCI). The volume of initial hemorrhage and initial neurological 
status following SAH remain major factors for mortality. Elderly patients and patients 
with coexisting medical conditions are at higher risk. The clinical goal is to prevent 
rebleeding and DCI [13–15].
In general, the prognosis of aneurysmal SAH is considered to be inversely related to 
grading at first presentation. Aggressive early interventions such as emergency surgical 
clip application or endovascular treatment of the aneurysm can lead to positive out-
comes in poor-grade aneurysmal SAH patients. Subarachnoid hemorrhage patients can 
be followed with conservative treatment without invasive intervention. External ven-
tricular drainage is a frequently preferred method in the case of hydrocephalus which 
can be observed during this clinical follow-up. In a multicenter, prospective observa-
tional study conducted with 324 patients, the relationship between the potential clini-
cal risk factors and the prognosis of aneurysmal SAH in intracranial aneurysm patients 
was investigated. Results showed that age, female gender, ventilated respiratory status, 
pupil dilatation, low GCS, WFNS grade, intraventricular hemorrhage, higher Fisher 
grade, higher Modified Fisher grade, and a relatively poor outcome in aneurysmal SAH 
patients receiving conservative treatment play a major role. There are many studies 
showing that age has a strong relationship with clinical outcomes in aneurysmal SAH 
patients [16–23]. Global cerebral edema occurs in up to 57% of patients suffering from 
subarachnoid hemorrhage and is associated with prolonged hospital stay and poor 
outcome. The pathogenesis of brain injury after intracerebral hemorrhage is thought 
to be due to mechanical damage followed by ischemic, cytotoxic, and inflammatory 
changes in the underlying and surrounding tissue. Typically, a sudden rise in intra-
cranial pressure at the moment of rupture reduces cerebral perfusion globally in both 
hemispheres and results in marked ischemic changes. Intraventricular extension of the 
hemorrhage and hydrocephalus may be a cause of coma, and thus, an improvement 
may be seen after ventriculostomy [3, 24, 25].
3. Delayed cerebral ischemia
Rebleeding after SAH remains one of the most serious early complications; 
the reported incidence is up to 15% in the first 24 hours, and the mortality rate is 
approximately 70% [26–28]. Prognosis is closely related to initial bleeding, rebleed-
ing, and DCI. The presence of intraventricular and intracerebral hemorrhage also 
adversely affects prognosis. Cardiac symptoms and neurogenic pulmonary edema 
are considered indicative of SAH severity. Hypernatremia after SAH is considered 
as a poor neurological marker. DCI generally begins approximately 3 days after 
bleeding, and its most severe presence is 1 week after bleeding. Smoking is con-
sidered as a risk factor for the development of DCI. The mechanism of DCI is not 
completely known, but the degree of initial bleeding is likely to be multifactorial 
with the severity of a function. It is also known that DCI occurs in cerebral regions 
without signs of angiographic vasospasm. The general recommendation is that 
angiographic vasospasm should not be treated in the absence of DCI.
DCI is usually treated by administration of nimodipine, via effect of maintenance 
of normal circulating blood volume and induced hypertension. Nimodipine is a cal-
cium antagonist, and its oral administration is useful in the treatment of vasospasm 
and DCI. IV application of nimodipine is not recommended. High-dose IV nicardip-
ine (0.15 mg/kg/hr for 14d) has been shown to reduce symptomatic vasospasm but 
not positively affect the 3-month neurological outcome in a prospective double-blind 
randomized controlled trial [4, 29–35].
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The clinical goal is to prevent rebleeding and DCI, because, in patients with 
SAH, DCI is considered the most important preventable cause of death and poor 
neurological prognosis. Delayed cerebral ischemia affects up to 30% of patients 
and leaves the majority of survivors with motor deficits, cognitive dysfunction, and 
reduced quality of life. The risk of developing DCI is associated with the severity of 
initial bleeding [36].
In patients with GCS 8 or less with intracranial hemorrhage, endotracheal 
intubation should be considered to protect the airway or to clear tracheal secretions. 
Intubation should be performed with a rapid induction with minimal effect on 
hemodynamics and not increasing intracranial pressure. Drugs used in induction 
should be preferred accordingly (e.g., propofol). It should be remembered that 
propofol may cause a drop in blood pressure. Preventive isotonic liquid bolus should 
be applied if necessary. Post-expiratory positive pressure (PEEP) up to 12 mmHg is 
considered safe as long as the mean arterial pressure is maintained [37].
4. Factors determining prognosis in subarachnoid hemorrhage
The prognosis after SAH may vary from severe disability to death, depending 
on the complications usually seen in the first 2 weeks associated with the severity of 
bleeding.
Common causes of this deterioration include neurological events such as hydro-
cephalus, seizures, ischemia, and systemic conditions, such as fever and infections, 
respiratory failure, and electrolyte abnormalities. The level of consciousness is 
considered the most important early predictor of outcome. For these reasons, 
patients presenting with a GCS score of less than 13 have traditionally been defined 
as having poor-grade SAH (classified as grade 4 and 5 according to the Hunt and 
Hess or the WFNS grading scales 5 or more recently as VASOGRADE-Red 6). Brain 
injury refers to the acute consequences of SAH-associated sudden increase of intra-
cranial pressure (ICP), which can cause decreased cerebral perfusion and transient 
global cerebral ischemia. The global cerebral ischemia can result in transient loss of 
consciousness or progressive intracranial hypertension [2, 38–41].
5. Complications and current treatment approaches
During aneurysmal SAH, extravasation of high-pressure arterial blood in the 
subarachnoid space is associated with a sudden ICP increase that, if severe and 
sustained, may compromise cerebral perfusion, causing global cerebral ischemia 
and early brain injury. Recently, the treatment of hypertension in intracranial 
hemorrhage patients has been discussed with INTERACT and ATACH training. The 
American Heart Association/American Stroke Association and Neurocritical Care 
guidelines include mean arterial blood pressure monitor, unsafe aneurysm types, 
and 110 or 160 mm Hg (or both) of the systolic blood bridge. Remember to keep it 
below 180 mm Hg. After aneurysm treatment, these parameters should not be made 
in such a way that spontaneous high blood pressure may be beneficial [29, 42–44].
Intracranial hypertension (ICP of at least 20 mm Hg) is a relatively common 
complication of SAH, especially in patients presenting with poor neurological con-
dition. Multiple factors such as cerebral edema, intraparenchymal hematoma, acute 
communicating hydrocephalus, intraventricular hemorrhage, aneurysm rerupture, 
complications related to aneurysm treatment, early brain injury, and DCI may con-
tribute to the development of intracranial hypertension. High ICP is associated with 
severe regulation of brain metabolism, increased risk of neurological deterioration, 
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and poor outcome, particularly in the absence of medical treatment. An ICP greater 
than 20 mm Hg is considered as an independent predictor of severe disability and 
death in aneurysmal SAH. Critical cerebral perfusion pressure levels (less than 
70 mm Hg) are significantly associated with cerebral infarction after SAH [45–51].
If the autoregulation mechanism is intact when intracranial pressure rises, the 
body tries to keep the cerebral blood flow (CBF) constant. As the ICP rises, the brain 
perfusion pressure drops. Systemic vascular resistance decreases, and vasodilata-
tion occurs at the limits of autoregulation to keep CBF stable. Cerebral blood flow is 
mainly regulated by arterial carbon dioxide tension (PaCO2). Abnormal PaCO2 levels 
are considered to cause major changes in CBF through vasoconstriction and vasodi-
lation, respectively, possibly contributing to further brain injury [52–56].
Main management principles of intracranial hypertension after SAH are tradi-
tionally guided by the literature on traumatic brain injury, due to high numbers. 
It should be noted that pathophysiology is completely different in our scenario. 
The role of therapies such as hyperosmolar agents, hypothermia, barbiturates and 
decompressive craniotomy is not clear in SAH patients with intracranial hyperten-
sion resistant to first-line therapies. The first approach to elevated ICP is cerebral 
venous drainage, normoventilation (PaCO2: 35–40 mm Hg), and positioning bed 
height from 30° to 45°. During sedation and aspiration of tracheal secretions and 
physiotherapy, neuromuscular blocking agents should be added if necessary. 
However, the role of these drugs for ICP management has not been fully estab-
lished, and some authors report that they may be more harmful than useful [57].
The use of hyperosmolar agents, such as mannitol and hypertonic saline, are 
current popular options in the treatment of high ICP in SAH.
Studies have shown that hypertonic saline is effective in controlling ICP and 
improving cerebral blood flow. The last treatment steps at highly resistant ICP 
include barbiturate, induced hypothermia, and decompressive craniectomy. 
Therapeutic hypothermia has been shown to be effective in controlling ICP in SAH 
but has not been shown to be associated with improved functional outcome and low 
mortality rates.
There are studies showing that hypertonic saline is more effective than man-
nitol in lowering ICP in traumatic brain injury. But however, there is no specific 
recommendation to select hypertonic saline or mannitol as the first line for patients 
with high ICP caused by traumatic brain injury [58–66]. Recent literature reports 
effectivity of hypertonic saline like mannitol in reducing of ICP in SAH. However 
further studies are needed to evaluate safest and optimal dose concentration and 
impact on improvement of outcomes.
Decompressive craniectomy, an important approach in refractory ICP in SAH 
patients, is often discussed in patients with poor prognosis. Decompressive crani-
ectomy has been associated with decreased mortality, significant decrease in ICP, 
increased cerebral oxygenation, and increased cerebral metabolism in many stud-
ies. However, severe disability or death was also observed in patients undergoing 
decompressive craniectomy for refractory ICP [67–72].
The hemodynamic approach, known as triple H therapy, has played a very 
important role in SAH treatment for many years. However, its safety and efficacy 
are discussed due to complications that may develop. In patients with SAH, a bolus 
normal saline fluid application is known to increase cerebral blood flow in areas 
of cerebral ischemia. The main purpose of fluid treatment in SAH is to maintain 
euvolemia and normal circulating blood volume. It should be noted that uncon-
trolled hypervolemia and hemodilution do not improve cerebral oxygen formation 
and may cause adverse events [73–77].
Noradrenaline perfusion may be added to the treatment to provide normotension 
in cases where appropriate blood pressure is not achieved despite fluid replacement 
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or in conditions limiting fluid therapy such as heart failure. If the pathology persists 
after blood pressure therapy in neurological examination, intravenous angioplasty 
or salvage therapy with intravenous infusion may be helpful. Prophylactic use of 
angioplasty is not recommended. Cardiac complications after SAH may vary from 
benign electrocardiogram changes to cardiogenic shock. Positive troponin value is 
common after SAH and is considered a good indicator of left ventricular dysfunc-
tion, which increases the risk of hypotension, pulmonary edema, and cerebral 
infarction. Treatment is symptomatic and most patients have spontaneous recovery 
within 2 weeks. However, aggressive ICU management may be necessary for severely 
impaired left ventricular functions. Dobutamine, levosimendan, milrinone, and even 
an intra-aortic balloon pump may be added to the treatment to maintain cerebral 
blood flow. It is known that the risk of heart failure and pulmonary complications is 
much higher in patients with low-grade SAH. Hypovolemia and pulmonary edema 
are known to increase the risk of delayed cerebral ischemia in this patient group. 
Long-term intensive care hospitalization may be required in SAH patients. This may 
result in pulmonary complications such as hospital-acquired pneumonia, cardiogenic 
or neurogenic pulmonary edema, aspiration pneumonia, and pulmonary embolism, 
which occurs in approximately 30% of patients.
Acute respiratory distress syndrome occurs in 27% of SAH patients and is an 
independent predictor of outcome. However, diuretics can be dangerous because 
of the risk of brain ischemia caused by hypovolemia. Early pulmonary edema and 
late pulmonary edema after SAH are caused by heart failure and inflammatory (i.e., 
non-cardiogenic) conditions, respectively.
Measurement of extravascular lung water index, cardiac index, and pulmonary 
vascular permeability index with Pulse Contour Cardiac Output (PiCCO) is consid-
ered to be useful in the identification of pulmonary edema in SAH patients [78–95]. 
Neither statin therapy nor magnesium infusions should be initiated for delayed cere-
bral ischemia. Cerebral vasospasm is just one component of delayed cerebral edema.
Hyponatremia is common in subarachnoid hemorrhage and is associated with 
longer hospitalization time, but not increased mortality. Sodium abnormalities are 
common and carry a risk of poor prognosis in acute SAH patients. We performed a 
10-year observational sodium study. Hyponatremia was defined as serum sodium 
(sNa) concentration below 135 mmol/L, whereas hypernatremia as sNa above 
150 mmol/L. Our 10-year targeted sodium management regimen in acute SAH 
patients showed that dysnatremias were frequent, predominantly hyponatremic 
state, due to cerebral salt wasting syndrome (CSW) and not syndrome of inappro-
priate antidiuretic hormone secretion (SIADH). Hypernatremia was shown to be 
an independent risk factor for inpatient mortality and poor outcome. The standard 
sodium protocol lowered the frequency of SIADH, which was encountered in only 
one patient over 5 years. However, it did not significantly reduce the incidence and 
outcome improvement of hyponatremia. Hypernatremia occurred more often and 
had a higher mortality and worse outcome than hyponatremia, but these patients 
were neurologically worse upon its onset. Hyponatremia is the most common 
electrolyte imbalance that occurs in 50% of patients after SAH. Two mechanisms 
are accepted for hyponatremia after SAH: CSW and SIADH. Cerebral salt wasting 
syndrome and SIADH have different pathogenesis. However, it is not always easy to 
distinguish in the clinic, and they can be observed in the same patient [96–100].
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